Advice
in the absence of a submission from the holder of the marketing authorisation:
apremilast (Otezla®) is not recommended for use within NHSScotland.
Indication under review: Treatment of adult patients with oral ulcers associated with Behçet’s disease who are candidates for systemic therapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice618KB (PDF)
Medicine details
- Medicine name:
- apremilast (Otezla)
- SMC ID:
- SMC2340
- Indication:
Treatment of adult patients with oral ulcers associated with Behçet’s disease who are candidates for systemic therapy.
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Ear, nose and oropharynx
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 February 2021